Manufacturer of Controlled Substances; Notice of Application, 55587 [E9-25899]
Download as PDF
55587
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices
The company plans to manufacture
the listed controlled substances as bulk
reagents for use in drug abuse testing.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 28, 2009.
Dated: October 16, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–25889 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 16, 2009,
American Radiolabeled Chemical, Inc.,
101 Arc Drive, St. Louis, Missouri
63146, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedules I and II:
erowe on DSK5CLS3C1PROD with NOTICES
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
Dimethyltryptamine (7435) ...........
1-[1-(2Thienyl)cyclohexyl]piperidine.
(7470) ...........................................
Dihydromorphine (9145) ...............
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Metazocine (9240) ........................
VerDate Nov<24>2008
15:34 Oct 27, 2009
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 220001
Drug
Schedule
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Phenazocine (9715) .....................
Fentanyl (9801) ............................
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 28, 2009.
Dated: October 16, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–25884 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 26, 2009,
Cayman Chemical Company, 1180 East
Ellsworth Road, Ann Arbor, Michigan
48108, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedule I:
Drug
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
I
I
The company plans to manufacture
small quantities of marihuana
derivatives for research purposes. In
reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol. In reference to
drug code 7370
(Tetrahydrocannabinols), the company
will manufacture a synthetic THC. No
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
other activity for this drug code is
authorized for registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 28, 2009.
Dated: October 16, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–25899 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 27, 2009,
Varian, Inc., Lake Forest, 25200
Commercentre Drive, Lake Forest,
California 92630–8810, made
application by renewal to the Drug
Enforcement Administration (DEA) as a
bulk manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Phencyclidine (7471) ....................
1-Piperidinocyclohexan- ................
carbonitrile (8603) .........................
Benzoylecgonine (9180) ...............
Schedule
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 28, 2009.
E:\FR\FM\28OCN1.SGM
28OCN1
Agencies
[Federal Register Volume 74, Number 207 (Wednesday, October 28, 2009)]
[Notices]
[Page 55587]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-25899]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on August 26, 2009, Cayman
Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,
made application by renewal to the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the basic classes of controlled
substances listed in schedule I:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
------------------------------------------------------------------------
The company plans to manufacture small quantities of marihuana
derivatives for research purposes. In reference to drug code 7360
(Marihuana), the company plans to bulk manufacture cannabidiol. In
reference to drug code 7370 (Tetrahydrocannabinols), the company will
manufacture a synthetic THC. No other activity for this drug code is
authorized for registration.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than December 28, 2009.
Dated: October 16, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-25899 Filed 10-27-09; 8:45 am]
BILLING CODE 4410-09-P